Subscribe Become an Author Sign Up Log In

Hunting Dark Genes For Druggable Targets

   by Tudor Oprea, Contributor    434    Comments 0

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Database    Drug Targets    Genes   

About one in three human proteins is understudied. Even when quantifying data is available from multiple sources, "dark" genes and proteins are simply not well characterized (Figure 1).

There may be multiple reasons why dark genes are ignored, although the literature isn't always in agreement with data availability.

Are you curious where dark gene hunting leads? There are a number of resources:

The development of pharmacological tools to probe the human proteome by 2035 is on its way. And some dark genes could play a role in precision medicine as well, along with other techniques. Of course, what makes a good drug target remains a matter of perspective.

To paraphrase Bengt Åblad, who led the discovery of metoprolol and felodipine (among other drugs), Go find a new drug target today!

Figure 1: SimpleDAS (simple data availability score) counts the association between a protein and 18 data types: publications and patents, gene and protein expression data, availability of 3D structures from X-ray, mouse phenotype associations and GWAS, protein-disease information as well as chemical bioactivity and drug data. Adapted from prior work.

Share this:              

You may also be interested to read:

 

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *